ONC Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

309.000

Open

307.250

VWAP

307.17

Vol

311.11K

Mkt Cap

36.63B

Low

303.560

Amount

95.56M

EV/EBITDA(TTM)

55.16

Total Shares

118.57M

233.72B

EV/OCF(TTM)

17.04

P/S(TTM)

10.26

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Events Timeline

(ET)

2026-06-30

06:30:00

BeOne Medicines MANGROVE Study Shows Brukinsa Significantly Improves MCL Patient Outcomes

2026-06-11 (ET)

2026-06-11

08:00:00

BeOne Medicines Presents Phase 3 Data for CLL in Elderly Patients

2026-05-27 (ET)

2026-05-27

17:10:00

BeOne Medicines Announces HERIZON-GEA-01 Trial Data

2026-05-13 (ET)

2026-05-13

13:30:00

BeOne Medicines Receives FDA Accelerated Approval for Beqalzi to Treat Lymphoma

News

4.5

06-30Yahoo Finance

SPDR S&P 500 ETF Trust Sees Marginal Increase

2.0

06-30Newsfilter

BRUKINSA Plus Rituximab Significantly Improves Outcomes in MCL Patients

5.0

06-25NASDAQ.COM

Kymera Therapeutics Appoints New Chairman of the Board

9.0

06-12Newsfilter

BeOne's Drug Shows Durable Efficacy in Chronic Lymphocytic Leukemia

2.0

06-11NASDAQ.COM

BeOne Medicines Stock Shows Oversold Signal

9.0

06-11Newsfilter

BRUKINSA Shows Long-Term Efficacy in Patients Over 80

11 Analyst Rating

Wall Street analysts forecast ONC stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

385.00

Averages

403.76

High

424.00

Current: 0.000

Low

385.00

Averages

403.76

High

424.00

Truist

Buy

maintain

$413 -> $416

AI Analysis

2026-07-07

New

Reason

Truist

Price Target

$413 -> $416

AI Analysis

2026-07-07

New

maintain

Buy

Reason

Truist raised the firm's price target on BeOne Medicines to $416 from $413 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.

RBC Capital

Outperform

maintain

$436 -> $451

2026-07-07

New

Reason

RBC Capital

Price Target

$436 -> $451

2026-07-07

New

maintain

Outperform

Reason

RBC Capital raised the firm's price target on BeOne Medicines to $451 from $436 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - driven by strong data expanding innovative spaces and perceptions around improving FDA flexibility/stability - and with outlooks more concretely definable than other high-volatility spaces, capital could continue to flow in, the analyst tells investors in a research note. Q2 earnings are shaping up to be seasonally strong, and with multiple opportunities for beats and the M&A resurgence likely to continue, there is little that would materially derail things, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ONC

Unlock Now

Valuation Metrics

The current forward P/E ratio for BeOne Medicines AG (ONC.O) is 44.05, compared to its 5-year average forward P/E of 69.40. For a more detailed relative valuation and DCF analysis to assess BeOne Medicines AG's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

69.40

Current PE

44.05

Overvalued PE

131.35

Undervalued PE

7.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

26.32

Current EV/EBITDA

18.28

Overvalued EV/EBITDA

60.49

Undervalued EV/EBITDA

-7.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.58

Current PS

4.31

Overvalued PS

6.65

Undervalued PS

4.52

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

run based on daily

Intellectia · 80 candidates

Ticker

Name

Market Cap$

SPOT

Spotify Technology SA

103.40B

COR

Cencora Inc

68.24B

AFL

Aflac Inc

56.90B

MSCI

MSCI Inc

44.25B

ONC

BeOne Medicines AG

40.49B

Consolidated Edison Inc

37.48B

Top Biotechnology/Health Tech

Intellectia · 82 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $10.00Annual Eps Yoy Growth: >= 10.0%Annual Revenue Yoy Growth: >= 10.0%

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

AZN

AstraZeneca PLC

280.73B

NVS

Novartis AG

278.44B

MCK

McKesson Corp

101.61B

ARGX

argenx SE

50.52B

ALNY

Alnylam Pharmaceuticals Inc

48.28B

SHORT SQEEZ STOCK

Intellectia · 362 candidates

Market Cap: 1000.00K - 1000.00BShort Ratio: MoreThan30Pct

Ticker

Name

Market Cap$

NVS

Novartis AG

278.44B

CVNA

Carvana Co

98.99B

HOOD

Robinhood Markets Inc

95.24B

COIN

Coinbase Global Inc

61.19B

GWW

WW Grainger Inc

50.33B

AXON

Axon Enterprise Inc

48.48B

Identify stocks with high short interest.

Intellectia · 365 candidates

Short Ratio: MoreThan30Pct

Ticker

Name

Market Cap$

TSLA

Tesla Inc

1.43T

NVS

Novartis AG

278.44B

CVNA

Carvana Co

98.99B

HOOD

Robinhood Markets Inc

95.24B

COIN

Coinbase Global Inc

61.19B

GWW

WW Grainger Inc

50.33B

Whales Holding ONC

Bluebox Asset Management Uk Ltd.

PRIMECAP Management Company

Franklin Templeton Sealand Fund Management Co., Ltd.

Bosera Asset Management Co., Ltd.

Wanjia Asset Management Co., Ltd.

Invesco Hong Kong Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is BeOne Medicines AG (ONC) stock price today?

The current price of ONC is 308.96 USD — it has decreased -0.16

What is BeOne Medicines AG (ONC)'s business?

What is the price predicton of ONC Stock?

Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.